RBC Capital Maintains Sector Perform on Fulcrum Therapeutics, Raises Price Target to $7

Benzinga · 10/30 14:58
RBC Capital analyst Luca Issi maintains Fulcrum Therapeutics (NASDAQ:FULC) with a Sector Perform and raises the price target from $5 to $7.